ETON — Eton Pharmaceuticals Share Price
Last trade - 00:00- $1.47bn
- $1.47bn
- $79.95m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 25.39 | ||
| PEG Ratio (f) | 0.47 | ||
| EPS Growth (f) | 117.63% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 31.49 | ||
| Price to Tang. Book | 1,617.61 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 13.89 | ||
| EV to EBITDA | 70.41 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 23.07% | ||
| Return on Equity | 35.97% | ||
| Operating Margin | 15.44% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 21.83 | 21.25 | 31.64 | 39.01 | 79.95 | 149.7 | 220.38 | 359.57% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | +90.08 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Eton Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company has over 11 commercial rare disease products: KHINDIVI, INCRELEX, ALKINDI SPRINKLE, DESMODA, GALZIN, HEMANGEOL, PKU GOLIKE, IMPAVIDO, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has four additional product candidates in late-stage development: Amglidia, ET-700, ET-800 and ZENEO hydrocortisone autoinjectors. INCRELEX (mecasermin) is used to treat children who are very short for their age because their bodies do not make enough insulin-like growth factor-1 (IGF-1). ALKINDI SPRINKLE is for the treatment of pediatric adrenocortical insufficiency. NITISINONE is a prescription medicine used to treat adults and children with a hereditary disease called tyrosinemia type 1 (HT-1). The Company also has licensed United States rights to a rare disease product candidate ASN-001 (timolol topical gel).
Directors
- Norbert Riedel NEC (63)
- Sean Brynjelsen PRE (49)
- W. Troutman CFO (66)
- Jennifer Adams IND (52)
- Charles Casamento IND (75)
- Paul Maier IND (73)
- Last Annual
- December 31st, 2025
- Last Interim
- June 30th, 2026
- Incorporated
- April 27th, 2017
- Public Since
- November 9th, 2018
- No. of Shareholders
- 4
- No. of Employees
- 44
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 28,583,135
- Address
- 21925 W Field Pkwy Ste 235, DEER PARK, 60010-7278
- Web
- https://etonpharma.com/
- Phone
- +1 null8004831140
- Auditors
- Grant Thornton LLP
Latest News for ETON
Upcoming Events for ETON
Q3 2026 Eton Pharmaceuticals Inc Earnings Release
Q4 2026 Eton Pharmaceuticals Inc Earnings Release
Similar to ETON
AC Immune AG
NASDAQ Global Market
ADMA Biologics
NASDAQ Global Market
ANI Pharmaceuticals
NASDAQ Global Market
Aquestive Therapeutics
NASDAQ Global Market
Aurinia Pharmaceuticals
NASDAQ Global Market
FAQ
As of Today at 02:32 UTC, shares in Eton Pharmaceuticals are trading at $51.33. This share price information is delayed by 15 minutes.
Shares in Eton Pharmaceuticals last closed at $51.33 and the price had moved by +168.04% over the past 365 days. In terms of relative price strength the Eton Pharmaceuticals share price has outperformed the S&P500 Index by +129.45% over the past year.
The overall consensus recommendation for Eton Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreEton Pharmaceuticals does not currently pay a dividend.
Eton Pharmaceuticals does not currently pay a dividend.
Eton Pharmaceuticals does not currently pay a dividend.
To buy shares in Eton Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $51.33, shares in Eton Pharmaceuticals had a market capitalisation of $1.47bn.
Here are the trading details for Eton Pharmaceuticals:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: ETON
Based on an overall assessment of its quality, value and momentum Eton Pharmaceuticals is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Eton Pharmaceuticals is $71.50. That is 39.29% above the last closing price of $51.33.
Analysts covering Eton Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of $1.18 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Eton Pharmaceuticals. Over the past six months, its share price has outperformed the S&P500 Index by +88.19%.
As of the last closing price of $51.33, shares in Eton Pharmaceuticals were trading +51.82% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Eton Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is 25.39. The shares last closed at $51.33.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Eton Pharmaceuticals' management team is headed by:
- Norbert Riedel - NEC
- Sean Brynjelsen - PRE
- W. Troutman - CFO
- Jennifer Adams - IND
- Charles Casamento - IND
- Paul Maier - IND